Our extensive Hatch-Waxman litigation practice and successful practice in post-grant PTO proceedings, combined with our deep technical expertise in biotechnology, uniquely positions us to develop and implement effective IP strategies for biosimilars. This industry-specific expertise is backed by one of the largest and most experienced biotechnology groups in IP law, with more than 75 attorneys and scientists representing clients in all stages of their business and technology development, as well a talented litigation group adept in all aspects of biotechnology IP law.
Our attorneys have the bench strength to help you successfully navigate the biosimilars pathway.
Up-to-date knowledge of biosimilars legislation
IP litigators with numerous trial and appellate successes
Extensive Hatch-Waxman litigation experience
Successful Post-Grant PTO practice on behalf of patent owners and petitioners
Over 20 attorneys with PhD’s in the life sciences
Extensive experience in biologics patent prosecution
Licensing and other transactional experience related to biologics
Count on our deep expertise across a spectrum of technologies.
Antibodies & Immunology
Research Tools & Reagents
Biological Manufacturing of Chemicals
Stem Cells & Regenerative Medicine
Australia National University
California Institute of Technology
Creative Peptides Sweden AB
Healthgen Biotechnology, Inc. in Wuhan
Hitachi Chemical Research Center
The National Institutes of Health
The University of California (UCSD, UCI, UCLA, UCSF)